Indian drugmakers are preparing for the launch of copycat weight-loss drugs as the world moves towards the patent expiry of ...

With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...

Currently, Hims & Hers can offer compounded semaglutide due to the patent-related supply shortages affecting patent holders ...

After years of shortages, the Food and Drug Administration (FDA) has now listed Novo Nordisk’s blockbuster diabetes and ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

"Don't risk your health trying to get healthy," she said. Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.

Not owning the “greatest stock out there” is better than owning the worst stock, according to Fundsmith boss Terry Smith.